Analog Devices Appoints Andrea F. Wainer to its Board of Directors

Rhea-AI Summary

Analog Devices (NASDAQ: ADI) has appointed Andrea F. Wainer to its Board of Directors as an independent director. Wainer will also serve on the Board's Nominating and Corporate Governance Committee. She currently serves as Executive Vice President of Rapid and Molecular Diagnostics at Abbott Laboratories, where she leads three businesses focused on molecular diagnostics, rapid point-of-care diagnostics, and hand-held point-of-care devices.

Wainer brings extensive healthcare sector experience from leadership positions at Abbott, Pfizer, and Astellas Pharma. Her previous roles include President of Abbott Molecular Diagnostics, President of Abbott Animal Health, and Divisional Vice President/General Manager of Abbott Renal Care. She holds a Bachelor's Degree in Accounting from Washington University and an MBA from Northwestern University.

Positive

• Addition of healthcare sector expertise to the board through appointment of experienced executive
• Strategic enhancement of leadership team with expertise in diagnostics and medical technology

Negative

• None.

News Market Reaction – ADI

+1.19%

1 alert

+1.19% News Effect

On the day this news was published, ADI gained 1.19%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

WILMINGTON, Mass., Jan. 22, 2025 /PRNewswire/ -- Analog Devices, Inc. (NASDAQ: ADI) today announced the appointment of Andrea F. Wainer, a seasoned healthcare executive, to its Board of Directors as an independent director. She will also serve as a member of the Board's Nominating and Corporate Governance Committee.

"We are delighted to welcome Andrea to the ADI Board, as her deep experience and leadership in the healthcare sector will provide ADI with an important source of wisdom and knowledge as we navigate the rich opportunity landscape ahead of us," said Vincent Roche, ADI's CEO and Chair.

Wainer is a highly versatile, results-oriented leader with expertise leading innovative businesses at Abbott Laboratories (Abbott), Pfizer and Astellas Pharma. Since 2019, she has served as Executive Vice President, Rapid and Molecular Diagnostics at Abbott. In this role, she leads three businesses – one focused on molecular diagnostics and the analysis of DNA and RNA at the molecular level, the second a provider of rapid point-of-care diagnostics, and the third delivers a leading hand-held point-of-care device.

Previous roles held include President, Abbott Molecular Diagnostics; President, Abbott Animal Health; and Divisional Vice President/General Manager, Abbott Renal Care.

Wainer also serves as a member of the Board of Trustees of the Goodman Theatre.

She earned a Bachelor's Degree in Accounting from the John M. Olin School of Business, Washington University and a Master's Degree in Business Administration from the Kellogg School of Management, Northwestern University.

About Analog Devices, Inc.
Analog Devices, Inc. (NASDAQ: ADI) is a global semiconductor leader that bridges the physical and digital worlds to enable breakthroughs at the Intelligent Edge. ADI combines analog, digital, and software technologies into solutions that help drive advancements in digitized factories, mobility, and digital healthcare, combat climate change, and reliably connect humans and the world. With revenue of more than $9 billion in FY24 and approximately 24,000 people globally, ADI ensures today's innovators stay Ahead of What's Possible. Learn more at www.analog.com and on LinkedIn and Twitter (X).

All trademarks and registered trademarks are the property of their respective owners.

CONTACT:
Ferda Millan
Global PR and External Communications
Analog Devices
CorpComm@analog.com
(408) 373-1854 

Michael Lucarelli
Vice President, Investor Relations and FP&A
Analog Devices
Investor.Relations@analog.com
(781) 461-3282

View original content to download multimedia:https://www.prnewswire.com/news-releases/analog-devices-appoints-andrea-f-wainer-to-its-board-of-directors-302356855.html

SOURCE Analog Devices, Inc.

FAQ

Who is the new board member appointed to Analog Devices (ADI)?

Andrea F. Wainer, Executive Vice President of Rapid and Molecular Diagnostics at Abbott Laboratories, has been appointed as an independent director to ADI's board.

What committees will Andrea Wainer serve on at ADI?

Andrea Wainer will serve on ADI's Nominating and Corporate Governance Committee.

What is Andrea Wainer's current role outside of ADI?

She serves as Executive Vice President of Rapid and Molecular Diagnostics at Abbott Laboratories, leading three businesses in molecular diagnostics and point-of-care devices.

What is the strategic significance of Andrea Wainer's appointment to ADI?

Her appointment brings deep healthcare sector expertise to ADI's board, providing strategic insights as the company explores opportunities in the healthcare and medical technology sectors.